Randomized phase 2 trial· 2021

Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial

Heymsfield SB|Coleman LA|Miller R|Rooks DS|Laurent D|Petricoul O|Praestgaard J|Swan T|Frost M|Vitolins MZ

JAMA Network Open

DOI
10.1001/jamanetworkopen.2020.33452
PubMed
33439265
Evidence level
strong
Verification
verified

Summary

A 48-week randomized phase 2 trial compared bimagrumab with placebo in adults with obesity and type 2 diabetes.

Limitations

Small phase 2 sample|Specific diabetes population|Intravenous monoclonal antibody|Not a peptide

Linked peptides

Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.